Is aggregate IAPP a cause of beta-cell failure in transplanted human pancreatic islets?

Current Diabetes Reports

Volumn 5, Issue 3, 2005, Pages 184-188

  Westermark, Per ^a   Andersson, Arne ^b   Westermark, Gunilla T ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ANTIDIABETIC AGENT; INSULIN; PRAMLINTIDE; AMYLIN;

AMINO ACID SEQUENCE; AMYLOIDOSIS; APOPTOSIS; CELL DEATH; CYTOTOXICITY; DISEASE ASSOCIATION; DRUG MECHANISM; GENETIC VARIABILITY; GRAFT FAILURE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INNER CELL MASS; INSULIN RESISTANCE; LANGERHANS CELL; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TREATMENT WITHDRAWAL; CHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; PANCREAS ISLET; PATHOLOGY; TREATMENT FAILURE;

AMYLOID; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; TREATMENT FAILURE;

EID: 27244452084     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0007-2     Document Type: Review

References (40)

1. Hull RL, Westermark CT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:3629-3643.
2. Rochet JC, Lansbury PTJ: Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000, 10:60-68.
3. Kayed R, Head E, Thompson JL, et al.: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
4. Kayed R, Sokolov Y, Edmonds B, et al.: Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279:46363-46366.
5. Yuan J, Yankner BA: Apoptosis in the nervous system. Nature 2000, 407:802-809.
6. Westermark P, Wernstedt C, Wilander E, et al.: A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986, 140:827-831.
7. Westermark P, Wernstedt C, Wilander E, et al.: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 1987, 84:3881-3885.
8. Cooper GJ, Willis AC, Clark A, et al.: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 1987, 84:8628-8632.
9. Wang J, Xu J, Finnerty J, et al.: The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 2001, 50:534-539.
10. Smeekens SP, Montag Ag, Thomas G, et al.: Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci U S A 1992, 89:8822-8826.
11. Ward WK, LaCava EC, Paquette TL, et al.: Disproportionate elevation of immunoreactive proinsulin in type 2 (noninsulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987, 30:698-702.
12. Westermark P, Li ZC, Westermark GT, et al.: Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 1996, 379:203-206.
13. Janciauskiene S, Eriksson S, Carlemalm E, Ahrén B: B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun 1997, 236:580-585.
14. Jaikaran ET, Clark A: Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001, 1537:179-203.
15. Westermark P: Amyloid and polypeptide hormones: what is their inter-relationship? Amyloid 1994, 1:47-60.
16. Westermark P, Engström U, Johnson KH, et al.: Islet amyloid polypeptide: pinpointing amino add residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 1990, 87:5036-5040.
17. Westermark P, Johnson KH, O'Brien TD, Betsholtz C: Islet amyloid polypeptide - a novel controversy in diabetes research. Diabetologia 1992, 35:297-303.
18. Westermark P, Grimelius L: The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. Acta Pathol Microbiol Scand [A] 1973, 81:291-300.
19. Clark A, Wells CA, Buley ID, et al.: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988, 9:151-159.
20. Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increase beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
21. Howard CFJ: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 1986, 29:301-306.
22. Johnson KH, O'Brien TD, Betsholtz C, Westermark P: Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989, 321:513-518.
23. Höppener JWM, Oosterwijk C, Nieuwenhuis MG, et al.: Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 1999, 42:427-434.
24. Verchere CB, D'Alessio DA, Palmiter RD, et al.: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 1996, 93:3492-3496.
25. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P: Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 2000, 6:998-1007.
26. Butler AE, Janson J, Soeller WC, Butler PC: Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52:2304-2314.
27. Butler AE, Jang J, Gurlo T, et al.: Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 2004, 53:1509-1516.
28. Ma Z, Westermark GT, Sakagashira S, et al.: Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 2001, 8:242-249.
29. Sakagashira S, Sanke T, Hanabusa T, et al.: Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996, 45:1279-1281.
30. O'Brien TD, Butler AE, Roche PC, et al.: Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 1994, 43:329-336.
31. Westermark GT, Steiner DF, Gebre-Medhin S, et al.: Pro islet amyloid polypeptide (proIAPP) immunoreactivity in amyloid formation in the islets of Langerhans. Upsala J Med Sci 2000, 105:97-106.
32. Westermark P, Eizirik DL, Pipeleers DG, et al.: Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 1995, 38:543-549.
33. Westermark GT, Westermark P, Eizirik D, et al.: Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice. Metabolism 1999, 48:448-454.
34. Shapiro AMJ, Lakey JRT, Ryan EA, et al.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid free immunosuppressive regiment. N Engl J Med 2000, 343:230-238.
35. Ryan EA, Lakey JRT, Paty BW, et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002, 51:2148-2157.
36. Street CN, Lakey JRT, Shapiro AMJ, et al.: Islet graft assessment in the Edmonton Protocol. Implications for predicting long-term clinical outcome. Diabetes 2004, 53:3107-3114.
37. Eizirik DL, Pipeleers DG, Ling Z, et al.: Major species differences between man and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci U S A 1994, 91:9253-9256.
38. Westermark GT, Westermark P, Nordin A, et al.: Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice. Upsala J Med Sci 2003, 108:193-204.
39. Kodama K, Hull RL, Wildbur S, et al.: Amyloid formation following islet transplantation is associated with increased beta-cell apoptosis, decreased beta-cell replication and reduced beta-cell volume [abstract]. Diabetes 2004, 53:A375-A376.
40. Westermark G, Benig Arora M, Fox N, et al.: Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1995, 1:542-543.